Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in thai hiv-infected children aged two years or less

Pediatric Infectious Disease Journal

Volumn 28, Issue 3, 2009, Pages 246-248

  Puthanakit, Thanyawee ^a   Aurpibul, Linda ^a   Sirisanthana, Thira ^a   Sirisanthana, Virat ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

HIV; Infants; NNRTI; Young children

Indexed keywords

EFAVIRENZ; GPOVIR S 30; LAMIVUDINE; NEVIRAPINE; STAVUDINE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; THAILAND; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; TREATMENT OUTCOME; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LAMIVUDINE; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; THAILAND; TREATMENT OUTCOME;

EID: 63449137208     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31818dd72b     Document Type: Article

References (15)

1. O'Brien DP, Sauvageot D, Zachariah R, et al. In resource-limited setting good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006;20:1955-1960.
2. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality of HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;44:599-604.
3. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-1342.
4. Wamalwa DC, Farquhar C, Obimbo EM, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45:311-317.
5. Faye A, Bertone C, Teglas JP, et al. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J. 2002;21:518-525.
6. Doerholt K, Duong T, Tookey P, et al. Outcomes for human immunodefi-ciancy virus-1 infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J. 2006;25:420-426.
7. Luzuriaga K, Manus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004;350:2471-2480.
8. O'Brien DP, Sauvageot D, Olson D, et al.; for Medecins Sans Frontieres. Treatment outcomes stratified by baseline immunological status among young infant receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings. Clin Infect Dis. 2007;44:1245-1248.
9. Violari A, Cotton M, Gibb D, et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. In: 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 22-25, 2007; Sydney, Australia.
10. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. Clin Infect Dis. 2005;41:100-107.
11. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Sustained immunologic and virologic efficacy after 4 years of highly active antiretroviral therapy in human immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J. 2007;26:953-956.
12. Linden DV, Hainaut M, Goetghrbuer T, et al. Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants. Pediatr Infect Dis J. 2007;26:359-361.
13. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135-147.
14. Ellis JC, L'homme RF, Ewings FM, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther. 2007;12:253-260.
15. L'homme RF, Kabamba D, Ewings FM, et al. Nevirapine, stavudine, and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS. 2008;22:557-565.